The VECTrans® technology exploits specific receptors selected for their high uptake/endocytosis and constitutive recycling capacity, thereby allowing significant intracellular transport and accumulation of therapeutic or imaging agents. Once the vector moiety of a vector-payload complex is locked onto the appropriate receptor at the surface of BBB endothelial cells, cancer cells or any target cell type expressing such receptors, the vector-payload complex undergoes rapid internalisation and subsequent intra/transcellular trafficking. This ultimately leads to payload delivery into cells and across the BBB into the brain via transport and transcytosis processes respectively thus modifying pharmacokinetic (PK) and distribution profile of therapeutic or imaging candidates.